Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

Researchers have found a potential new way to improve the treatment of multiple sclerosis (MS) using a novel combined therapy. The results build on two harmonized Phase I clinical trials, focusing on ...

A potential new therapy for multiple sclerosis, as doctors say the new treatment has the potential to turn back the hands of time. University of California scientists worked for 10 years on a drug ...

Multiple sclerosis (MS) is a long-term disease where the immune system mistakenly attacks the protective layer around nerve cells, known as the myelin sheath. This leads to nerve damage and worsening ...

CombiRx is a randomized clinical trial to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in ...

The nerve damage caused by multiple sclerosis (MS) can disrupt a person’s ability to walk, balance, and even carry out the most basic everyday activities. Staying physically active can improve sleep ...

Cognitive behavioral therapy and the mild stimulant modafinil both reduce fatigue in people with multiple sclerosis by about the same amount, finds a new study. Combining talk therapy and medication ...

Key updates in disease-modifying therapies for relapsing-remitting multiple sclerosis (RRMS) from the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) forum are reported ...